

Lennart T H Jacobsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9289235/publications.pdf>

Version: 2024-02-01

76
papers

2,814
citations

218592

26
h-index

197736

49
g-index

78
all docs

78
docs citations

78
times ranked

3281
citing authors

#	ARTICLE	IF	CITATIONS
1	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 374-384.	0.6	7
2	Association between perinatal factors and future risk for gout—a nested case-control study. <i>Arthritis Research and Therapy</i> , 2022, 24, 60.	1.6	2
3	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	0.9	6
4	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. <i>Rheumatology</i> , 2022, 61, 3647-3656.	0.9	2
5	Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. <i>Rheumatology</i> , 2021, 60, 2725-2734.	0.9	19
6	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. <i>Rheumatology</i> , 2021, 60, 140-146.	0.9	4
7	Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis. <i>Rheumatology</i> , 2021, 60, 1804-1813.	0.9	3
8	Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2021, 40, 1321-1329.	1.0	7
9	Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a <i>post-hoc</i> analysis of pooled data from three phase 3 trials with secukinumab. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab009.	0.3	1
10	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. <i>Rheumatology</i> , 2021, 60, e262-e263.	0.9	0
11	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1512-1518.	1.0	5
12	Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. <i>RMD Open</i> , 2021, 7, e001568.	1.8	12
13	Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis—an inception cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 169.	1.6	18
14	Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1445-1452.	0.5	21
15	Comment on: Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: results from a national register-based cohort study. Reply. <i>Rheumatology</i> , 2021, , .	0.9	0
16	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 3635-3645.	0.9	14
17	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020, 59, 1640-1650.	0.9	18
18	The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors—30 years follow-up of the Malmö Preventive Project. <i>Arthritis Research and Therapy</i> , 2020, 22, 244.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Occupational exposure to inorganic dust and risk of gout: a population-based study. RMD Open, 2020, 6, e001178.	1.8	3
20	Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology, 2020, 16, 380-390.	3.5	562
21	Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot. Arthritis Research and Therapy, 2020, 22, 37.	1.6	13
22	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	0.9	7
23	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors' data from a large national quality register. Arthritis Research and Therapy, 2020, 22, 15.	1.6	19
24	Dual energy CT findings in gout with rapid kilovoltage-switching source with gemstone scintillator detector. BMC Rheumatology, 2020, 4, 7.	0.6	5
25	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology, 2020, 59, 3229-3236.	0.9	30
26	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
27	A randomized study comparing regular care with a nurse-led clinic based on tight disease activity control and person-centred care in patients with rheumatoid arthritis with moderate/high disease activity: A 6-month evaluation. Musculoskeletal Care, 2019, 17, 215-225.	0.6	8
28	CD21 ^{low} B cells associate with joint damage in rheumatoid arthritis patients. Scandinavian Journal of Immunology, 2019, 90, e12792.	1.3	33
29	Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. Alzheimer's and Dementia, 2019, 15, 754-763.	0.4	58
30	The Validity of Gout Diagnosis in Primary Care: Results from a Patient Survey. Journal of Rheumatology, 2019, 46, 1531-1534.	1.0	12
31	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	0.9	23
32	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD Open, 2019, 5, e001079.	1.8	17
33	SAT0138...PREDICTORS OF CLINICAL EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS: DATA FROM A LARGE OBSERVATIONAL STUDY. , 2019, , .		0
34	Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open, 2019, 5, e001053.	1.8	11
35	Dr. Dehlin, <i>et al</i> reply. Journal of Rheumatology, 2019, 46, 1542.2-1542.	1.0	0
36	Prevalence and incidence of non-gout crystal arthropathy in southern Sweden. Arthritis Research and Therapy, 2019, 21, 291.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 17.	1.6	92
38	Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 541-548.	0.5	34
39	Trends in Gout Hospitalization in Sweden. <i>Journal of Rheumatology</i> , 2018, 45, 145-146.	1.0	8
40	Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. <i>Rheumatology</i> , 2018, 57, 1173-1179.	0.9	12
41	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. <i>Journal of Rheumatology</i> , 2018, 45, 779-784.	1.0	10
42	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e1-e1.	0.5	6
43	Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology International</i> , 2018, 38, 275-282.	1.5	2
44	Work disability in gout: a population-based case-control study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 399-404.	0.5	19
45	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. <i>RMD Open</i> , 2018, 4, e000655.	1.8	21
46	Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex. <i>Arthritis Research and Therapy</i> , 2018, 20, 284.	1.6	55
47	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 218.	1.6	41
48	Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 108.	1.6	29
49	The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden. <i>Arthritis Research and Therapy</i> , 2018, 20, 190.	1.6	14
50	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Current Therapeutic Research</i> , 2018, 89, 1-6.	0.5	19
51	Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1495-1501.	0.5	63
52	Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 105-111.	0.5	97
53	Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 364-370.	0.5	88
54	Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 688-693.	0.5	55

#	ARTICLE	IF	CITATIONS
55	Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1515-1521.	0.5	92
56	Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2017, 44, 981-987.	1.0	23
57	Factors associated with initiation and persistence of urate-lowering therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 6.	1.6	32
58	Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 102.	1.6	111
59	Incidence and prevalence of gout in Western Sweden. <i>Arthritis Research and Therapy</i> , 2016, 18, 164.	1.6	73
60	Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2087-2094.	0.5	67
61	Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. <i>RMD Open</i> , 2016, 2, e000326.	1.8	28
62	Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. <i>Arthritis Research and Therapy</i> , 2016, 18, 240.	1.6	15
63	Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 499.	0.8	11
64	Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case-control study based on national registers. <i>Arthritis Research and Therapy</i> , 2016, 18, 16.	1.6	6
65	Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden. <i>Journal of Rheumatology</i> , 2016, 43, 81-87.	1.0	33
66	Seasonal variations in fatigue in persons with rheumatoid arthritis: a longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 59.	0.8	17
67	Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 106.	0.8	21
68	Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1838-1842.	0.5	66
69	A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women. <i>Rheumatology</i> , 2016, 55, 307-314.	0.9	33
70	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 993-997.	0.5	100
71	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. <i>Arthritis Research and Therapy</i> , 2015, 17, 118.	1.6	77
72	Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. <i>Rheumatology</i> , 2015, 54, 1186-1193.	0.9	44

#	ARTICLE	IF	CITATIONS
73	Validity of gout diagnosis in Swedish primary and secondary care—a validation study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 149.	0.8	34
74	Body mass index and the risk of giant cell arteritis—results from a prospective study. <i>Rheumatology</i> , 2015, 54, 433-440.	0.9	33
75	Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects. <i>PLoS ONE</i> , 2014, 9, e113602.	1.1	19
76	Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2005-2013.	0.9	187